Nyg Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.91 M
as on 13-12-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -20.31%
(FY 2022)
- Profit 83.15%
(FY 2022)
- Ebitda 84.03%
(FY 2022)
- Net Worth -12.46%
(FY 2022)
- Total Assets 24.08%
(FY 2022)
About Nyg Pharmaceuticals
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.91 M, as per Ministry of Corporate Affairs (MCA) records.
Sat Singh, Sunil Chhikara, and Anil Kumar serve as directors at the Company.
- CIN/LLPIN
U74999DL2017PTC314046
- Company No.
314046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Mar 2017
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nyg Pharmaceuticals Private Limited offer?
Nyg Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Nyg Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sat Singh  | Director | 07-Mar-2017 | Current |
| Sunil Chhikara | Director | 07-Mar-2017 | Current |
| Anil Kumar | Director | 07-Mar-2017 | Current |
Financial Performance of Nyg Pharmaceuticals.
Nyg Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 20.31% decrease. The company also saw a substantial improvement in profitability, with a 83.15% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nyg Pharmaceuticals?
Unlock access to Nyg Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nyg Pharmaceuticals?
Unlock and access historical data on people associated with Nyg Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nyg Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nyg Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
